JNTU B.Pharmacy III GENERIC PRODUCT DEVELOPMENT Previous Question Paper (August -2022 - R17)

The selection of a generic drug product is a strategic decision that balances market potential with technical feasibility. Key considerations include:

• Market Analysis: Evaluation of the current market size, growth trends, and the number of existing competitors. High-volume products with limited generic competition are prioritized.
• Patent and Exclusivity Status: Thorough investigation of the Orange Book to identify patent expiry dates and periods of market exclusivity, ensuring the product can be legally launched upon patent expiration.
• Technical Feasibility: Assessment of the complexity of the formulation, availability of Active Pharmaceutical Ingredients (API), and the capability of existing manufacturing facilities to handle specific dosage forms (e.g., sterile injectables vs. solid orals).
• Regulatory Requirements: Understanding the specific bioequivalence requirements and the complexity of the Abbreviated New Drug Application (ANDA) submission process for the target molecule.
• Cost and Profitability: Analysis of the cost of goods sold (COGS), including raw material sourcing and manufacturing overheads, against expected pricing in a competitive generic market.
• Supply Chain Stability: Ensuring a reliable supply of high-quality API and excipients to prevent interruptions in production.

Exclusivity refers to the period of time granted by the FDA that prevents the approval of competing generic drug applications for a specific drug product. Unlike patents, which are granted by the USPTO, exclusivity is a statutory provision that provides protection from competition regardless of patent status.

Types of exclusivity include:

• New Chemical Entity (NCE) Exclusivity: Granted for 5 years to drugs containing active ingredients never previously approved by the FDA.
• Orphan Drug Exclusivity: Granted for 7 years to drugs developed for rare diseases or conditions affecting fewer than 200,000 people in the US.
• Pediatric Exclusivity: Provides an additional 6 months of market protection if the manufacturer conducts requested pediatric studies.
• Generating Antibiotic Incentives Now (GAIN) Exclusivity: Provides an additional 5 years of exclusivity for qualified infectious disease products.
• Other Exclusivity: Includes 3-year exclusivity for new clinical investigations (e.g., new dosage forms or new indications) essential to the approval of a drug.